Видео с ютуба (Hnscc)

Expanding Immune Options in LA and RM HNSCC

Lymphatic ctDNA: Superior Detection of Residual Disease in HPV-Independent HNSCC

Weekly second-line PTC after immunotherapy progression in HNSCC

Metronomic chemotherapy and cemiplimab in recurrent/metastatic HNSCC

Lymphatic ctDNA: A Powerful Tool for Detecting Residual Disease in HNSCC

ASPEN-03: evorpacept & pembrolizumab in unresectable, PD-L1+ R/M HNSCC

OrigAMI-4: amivantamab monotherapy in previously treated R/M HNSCC

ASPEN-04: evorpacept with pembrolizumab & chemotherapy in R/M HNSCC

Oncology Update – October 27, 2025: Breakthrough HNSCC Combo, Kisqali 5-Year Data and More

Watch Teulings & Bhatia discuss #HNSCC updates from #JADPROLive -

Staying ahead of the curve in HNSCC care: Refining the role of immunotherapy across disease stages

БУРАН: бупарлисиб и паклитаксел при предварительно леченном плоскоклеточном раке головы и шеи

Buparlisib and Paclitaxel: A Missed Opportunity for OS Improvement in HNSCC

ADRISK: пембролизумаб плюс адъювантная химиолучевая терапия при плоскоклеточном раке головы и шеи

Global Perspectives on Perioperative Immunotherapy in LA HNSCC

Rationale for Combining Radiation and Immunotherapy in Resectable Locally Advanced HNSCC

The Evolving Landscape of Resectable Locally Advanced HNSCC

Emerging Evidence for Perioperative ICIs in Locally Advanced HNSCC

Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab

🎙️ Episode 10 : Pembrolizumab Reshaping Head and Neck Cancer Treatment : KEYNOTE-689 | Dr. Pidugu